Ehmet Health — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Ehmet Health is an emerging innovator in the radiopharmaceuticals and medical device sector, focusing on making advanced radiotherapy more accessible and efficient. The company's technology portfolio centers on two main platforms: a scalable, synchrotron-based proton therapy system (KODA ONE) and a specialized, self-shielded breast radiotherapy system. By emphasizing modular design, unified software, and patient-centric solutions, Ehmet aims to lower the cost and complexity barriers associated with high-precision radiation therapy, targeting a significant global market need. The company is privately held and appears to be in a pre-revenue or early commercial stage as it deploys its initial systems.

Oncology

Technology Platform

Unified radiotherapy platforms featuring: 1) KODA ONE - a scalable, synchrotron-based proton therapy system with modular 1-4 room buildout, pencil beam scanning, and integrated 3D imaging, managed by a unified software ecosystem. 2) A dedicated breast radiotherapy system with a rotational LINAC for dose homogeneity and self-shielded design for compact installation.

Opportunities

The global push to expand radiotherapy access, especially in emerging markets, aligns perfectly with Ehmet's scalable and compact system designs.

There is a significant unmet need for more affordable and space-efficient proton therapy, and a high-volume opportunity for specialized breast cancer treatment systems that improve outcomes and clinic workflow.

Risk Factors

Key risks include technological and execution risk as a new entrant competing against established giants, significant market adoption risk due to long sales cycles and high capital costs for customers, and financial risk from high burn rates and dependence on investor funding until sustainable revenue is achieved.

Competitive Landscape

Ehmet Health competes in the advanced radiotherapy market against large, established players like Varian (Siemens Healthineers) and Elekta in linear accelerators, and Ion Beam Applications (IBA), Mevion, and ProTom in proton therapy. Its differentiation lies in scalability, modularity, and a unified software platform aimed at lowering cost and complexity barriers.

More companies in Radiopharmaceuticals →More companies in United States →